These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 31988506)

  • 1. Pro-efferocytic nanoparticles are specifically taken up by lesional macrophages and prevent atherosclerosis.
    Flores AM; Hosseini-Nassab N; Jarr KU; Ye J; Zhu X; Wirka R; Koh AL; Tsantilas P; Wang Y; Nanda V; Kojima Y; Zeng Y; Lotfi M; Sinclair R; Weissman IL; Ingelsson E; Smith BR; Leeper NJ
    Nat Nanotechnol; 2020 Feb; 15(2):154-161. PubMed ID: 31988506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pro-efferocytic nanotherapies reduce vascular inflammation without inducing anemia in a large animal model of atherosclerosis.
    Bamezai S; Zhang Y; Kumari M; Lotfi M; Alsaigh T; Luo L; Kumar GS; Wang F; Ye J; Puri M; Manchanda R; Paluri S; Adkar SS; Kojima Y; Ingelsson A; Bell CF; Lopez NG; Fu C; Choi RB; Miller Z; Barrios L; Walsh S; Ahmad F; Maegdefessel L; Smith BR; Leeper NJ
    Nat Commun; 2024 Sep; 15(1):8034. PubMed ID: 39271657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A nano-bioconjugate modified with anti-SIRPα antibodies and antisense oligonucleotides of mTOR for anti-atherosclerosis therapy.
    Liu Y; Huang Q; He M; Chen T; Chu X
    Acta Biomater; 2024 Mar; 176():356-366. PubMed ID: 38160854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The regulation of CD47-SIRPα signaling axis by microRNAs in combination with conventional cytotoxic drugs together with the help of nano-delivery: a choice for therapy?
    Beizavi Z; Gheibihayat SM; Moghadasian H; Zare H; Yeganeh BS; Askari H; Vakili S; Tajbakhsh A; Savardashtaki A
    Mol Biol Rep; 2021 Jul; 48(7):5707-5722. PubMed ID: 34275112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clonally expanding smooth muscle cells promote atherosclerosis by escaping efferocytosis and activating the complement cascade.
    Wang Y; Nanda V; Direnzo D; Ye J; Xiao S; Kojima Y; Howe KL; Jarr KU; Flores AM; Tsantilas P; Tsao N; Rao A; Newman AAC; Eberhard AV; Priest JR; Ruusalepp A; Pasterkamp G; Maegdefessel L; Miller CL; Lind L; Koplev S; Björkegren JLM; Owens GK; Ingelsson E; Weissman IL; Leeper NJ
    Proc Natl Acad Sci U S A; 2020 Jul; 117(27):15818-15826. PubMed ID: 32541024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ERV1/ChemR23 Signaling Protects Against Atherosclerosis by Modifying Oxidized Low-Density Lipoprotein Uptake and Phagocytosis in Macrophages.
    Laguna-Fernandez A; Checa A; Carracedo M; Artiach G; Petri MH; Baumgartner R; Forteza MJ; Jiang X; Andonova T; Walker ME; Dalli J; Arnardottir H; Gisterå A; Thul S; Wheelock CE; Paulsson-Berne G; Ketelhuth DFJ; Hansson GK; Bäck M
    Circulation; 2018 Oct; 138(16):1693-1705. PubMed ID: 29739755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Palmitoylethanolamide Promotes a Proresolving Macrophage Phenotype and Attenuates Atherosclerotic Plaque Formation.
    Rinne P; Guillamat-Prats R; Rami M; Bindila L; Ring L; Lyytikäinen LP; Raitoharju E; Oksala N; Lehtimäki T; Weber C; van der Vorst EPC; Steffens S
    Arterioscler Thromb Vasc Biol; 2018 Nov; 38(11):2562-2575. PubMed ID: 30354245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of Pro-resolving and Pro-efferocytic Nanoparticles for Atherosclerosis Therapy.
    Patel Y; Manturthi S; Tiwari S; Gahunia E; Courtemanche A; Gandelman M; Côté M; Gadde S
    ACS Pharmacol Transl Sci; 2024 Oct; 7(10):3086-3095. PubMed ID: 39416959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functions and molecular mechanisms of the CD47-SIRPalpha signalling pathway.
    Matozaki T; Murata Y; Okazawa H; Ohnishi H
    Trends Cell Biol; 2009 Feb; 19(2):72-80. PubMed ID: 19144521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer immunotherapy targeting the CD47/SIRPα axis.
    Weiskopf K
    Eur J Cancer; 2017 May; 76():100-109. PubMed ID: 28286286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD47-SIRPα Interactions Regulate Macrophage Uptake of Plasmodium falciparum-Infected Erythrocytes and Clearance of Malaria In Vivo.
    Ayi K; Lu Z; Serghides L; Ho JM; Finney C; Wang JCY; Liles WC; Kain KC
    Infect Immun; 2016 Jul; 84(7):2002-2011. PubMed ID: 27091932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis.
    Kojima Y; Volkmer JP; McKenna K; Civelek M; Lusis AJ; Miller CL; Direnzo D; Nanda V; Ye J; Connolly AJ; Schadt EE; Quertermous T; Betancur P; Maegdefessel L; Matic LP; Hedin U; Weissman IL; Leeper NJ
    Nature; 2016 Aug; 536(7614):86-90. PubMed ID: 27437576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional characterization of the selective pan-allele anti-SIRPα antibody ADU-1805 that blocks the SIRPα-CD47 innate immune checkpoint.
    Voets E; Paradé M; Lutje Hulsik D; Spijkers S; Janssen W; Rens J; Reinieren-Beeren I; van den Tillaart G; van Duijnhoven S; Driessen L; Habraken M; van Zandvoort P; Kreijtz J; Vink P; van Elsas A; van Eenennaam H
    J Immunother Cancer; 2019 Dec; 7(1):340. PubMed ID: 31801627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. "Velcro" engineering of high affinity CD47 ectodomain as signal regulatory protein α (SIRPα) antagonists that enhance antibody-dependent cellular phagocytosis.
    Ho CC; Guo N; Sockolosky JT; Ring AM; Weiskopf K; Özkan E; Mori Y; Weissman IL; Garcia KC
    J Biol Chem; 2015 May; 290(20):12650-63. PubMed ID: 25837251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy.
    Schürch CM; Roelli MA; Forster S; Wasmer MH; Brühl F; Maire RS; Di Pancrazio S; Ruepp MD; Giger R; Perren A; Schmitt AM; Krebs P; Charles RP; Dettmer MS
    Thyroid; 2019 Jul; 29(7):979-992. PubMed ID: 30938231
    [No Abstract]   [Full Text] [Related]  

  • 16. 2021 Jeffrey M. Hoeg Award Lecture: Defining the Role of Efferocytosis in Cardiovascular Disease: A Focus on the CD47 (Cluster of Differentiation 47) Axis.
    Jarr KU; Kojima Y; Weissman IL; Leeper NJ
    Arterioscler Thromb Vasc Biol; 2022 Jun; 42(6):e145-e154. PubMed ID: 35387480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LncRNA MIAT sponges miR-149-5p to inhibit efferocytosis in advanced atherosclerosis through CD47 upregulation.
    Ye ZM; Yang S; Xia YP; Hu RT; Chen S; Li BW; Chen SL; Luo XY; Mao L; Li Y; Jin H; Qin C; Hu B
    Cell Death Dis; 2019 Feb; 10(2):138. PubMed ID: 30755588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sonodynamic Therapy Promotes Efferocytosis via CD47 Down-Regulation in Advanced Atherosclerotic Plaque.
    Cao Y; Yao J; Gao W; Cao Z; Diabakte K; Wang L; Sun X; Tian Y
    Int Heart J; 2022 Jan; 63(1):131-140. PubMed ID: 35034916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of Cell Surface CD47 Clustering Formation and Binding Avidity to SIRPα Facilitate Apoptotic Cell Clearance by Macrophages.
    Lv Z; Bian Z; Shi L; Niu S; Ha B; Tremblay A; Li L; Zhang X; Paluszynski J; Liu M; Zen K; Liu Y
    J Immunol; 2015 Jul; 195(2):661-71. PubMed ID: 26085683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SIRPα-CD47 Immune Checkpoint Blockade in Anticancer Therapy.
    Veillette A; Chen J
    Trends Immunol; 2018 Mar; 39(3):173-184. PubMed ID: 29336991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.